Every material Form 8-K UNITED GUARDIAN INC has filed with the SEC since May 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
United-Guardian reported second-quarter 2026 net sales of $3,108,267, up 10% from $2,838,225 a year earlier, and net income of $728,579 ($0.16 per share), up 16% from $626,826 ($0.14 per share). For the first half, net sales rose 12% to $5,980,489 and net income rose 30% to $1,547,481 ($0.34 per share), which included $339,493 of settlement income that the company did not report in the 2025 period.
Q2 2026 cosmetic ingredient sales rose 44%, mainly from higher purchases by Ashland Specialty Ingredients, after its 2025 inventory levels were reduced.
Q2 2026 pharmaceutical sales rose 1%; first-half pharmaceutical sales rose 11%, with Renacidin the primary driver.
First-half 2026 settlement income was $339,493, compared with none in the first half of 2025.
United-Guardian's Board declared a cash dividend of $0.30 per share, payable August 4, 2026, to holders of record on July 28, 2026. The company says this is a 20% increase over the dividend paid in February and its 31st consecutive year of dividend payments.
Dividend of $0.30 per share declared by the Board at its July 14, 2026 meeting
Payment date is August 4, 2026; record date is July 28, 2026
Stated increase of 20% over the dividend paid in February 2026
United-Guardian reported first quarter 2026 net sales of $2,872,222, up from $2,481,127 a year earlier, and net income of $818,902 ($0.18 per share), up from $560,895 ($0.12 per share). The company said the gain was driven by higher pharmaceutical and cosmetic ingredient sales, and also included $303,133 of settlement income from its contract manufacturer of Renacidin.
Net sales rose to $2,872,222 in Q1 2026 from $2,481,127 in Q1 2025.
Net income rose to $818,902 ($0.18 per share) from $560,895 ($0.12 per share).
Settlement income of $303,133 from the Renacidin contract manufacturer contributed to the quarter's results; income from operations was $642,449 versus $610,922.
Management said Ashland Specialty Ingredients' purchases rose 45% year over year after it worked through excess inventory.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every UNITED GUARDIAN INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →